On July 30, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company") reported it has completed the second tranche of its institutional placement (Placement), details of which were announced to the market on June 21, 2021 (Press release, Immutep, JUL 30, 2021, View Source [SID1234585533]). The second tranche of the Placement comprises the issue of 88,970,717 new ordinary fully paid shares in the Company (Tranche 2 Shares) at an issue price of A$0.52 per Tranche 2 Share to raise approximately A$46.3 million. The issue of these shares was as approved by the Company’s shareholders at its Extraordinary General Meeting held on July 26, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Net proceeds from the now completed A$60 million two-tranche Placement and the recently completed Share Purchase Plan (SPP) which raised A$7.2 million (details of which were announced to ASX on July 21, 2021) bring the total funds raised under the Placement and SPP to approximately A$67.2 million. These funds will be used to support Immutep’s ongoing and planned immuno-oncology clinical development programs, its pre-clinical program in autoimmune disease and for general working capital purposes.

The Tranche 2 Shares were issued today and will commence trading on ASX on Monday, August 2, 2021.

On July 30, 2021 Prescient Therapeutics (PTX) reported that it has summarised its operations and cashflow for the June quarter (Press release, Prescient Therapeutics, JUL 30, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-advances-clinical-studies-in-june-quarter [SID1234585506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.

In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).

This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn’t observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.

Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.

A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.

In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.

Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.

The healthcare stock ended the quarter with $16.09 million in cash.

Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.

On July 30, 2021 NEC reported that (Press release, NEC, JUL 30, 2021, View Source [SID1234585489])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for the Three-month Period Ended June 30, 2021 (April 1, 2021 – June 30, 2021)

(2) Consolidated Financial Position

2. Dividends

3. Consolidated Financial Results Forecast for the Year Ending March 31, 2022 (April 1, 2021 – March 31, 2022)

*This consolidated financial results falls outside the scope of quarterly review procedures to be performed by certified public accountants or an audit firm. *Explanation concerning the appropriate use of the financial results forecast and other special matters (Adjusted profit (loss)) "Adjusted operating profit (loss)" is an indicator for measuring underlying profitability in order to clarify the contribution of acquired companies to the NEC Group’s overall earnings. It is measured by deducting amortization of intangible assets recognized as a result of M&A and expenses for acquisition of companies (financial advisory fees and other fees) from operating profit (loss). Also, "Adjusted net profit (loss) attributable to owners of the parent" is an indicator for measuring underlying profitability attributable to owners of the parent. It is measured by deducting adjustment items of operating profit (loss) and corresponding amounts of tax and non-controlling interests from net profit (loss) attributable to owners of the parent.

1. Condensed Interim Consolidated Financial Statements and Notes to Condensed Interim Consolidated Financial Statements

On July 30, 2021 Generic Health, the Australia based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin) reported that it has entered into a definitive agreement under which Lupin will acquire 100% of the shares of Southern Cross Pharma Pty Ltd (SCP) (Press release, Lupin, JUL 30, 2021, View Source [SID1234585487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Incorporated in Melbourne, Australia, SCP is engaged in developing, registering, and distributing generic products. As a part of the transaction, Generic Health will gain access to over 60 registered products having sales of over AUD 30 Mn (approximately USD 22 Mn). This will significantly increase Lupin’s value proposition and market share in the Australian market.

Commenting on the acquisition, Nilesh Gupta, Managing Director Lupin said, "This is an important acquisition for our Australian entity and is aligned with Lupin’s strategy to expand and deepen our presence in select markets of focus. The Southern Cross Pharma portfolio builds on our existing portfolio of prescription generics, over the counter and specialty range of products. This investment significantly increases our scale in Australia and reinforces our commitment to patients in Australia." "The acquisition of SCP marks the next exciting chapter of growth for Generic Health. We will benefit from SCP’s portfolio of over 60 difficult-to-develop generic pharmaceutical products. This substantially strengthens our product offering and enables us to deliver enhanced value for our stakeholders, patients and communities," said Ashutosh Damle, CEO, Generic Health.

Neill Stacey, Managing Director and owner of SCP commented, "Over the past 20 years, SCP has had a preference to develop a portfolio of products that are more demanding than the standard generics. I am happy that the reach of Southern Cross Pharma’s products will increase through Lupin and Generic Health."

On July 30, 2021 Guangzhou Lupeng Pharmaceutical reported that it completed a $35 million pre-B financing led by Temasek (Press release, Guangzhou Lupeng Pharmaceutical, JUL 30, 2021, View Source [SID1234585481]). The company will use the funds for global clinical development of its lead drug, a selective Bcl-2 inhibitor, along with advancing at least four other candidates into clinical trials. Founded in 2018, Lupeng aims to develop global best-in-class therapies. The company develops novel small molecule drugs for cancer, hepatitis B and autoimmune diseases. Lupeng is approved to conduct clinical trials of its lead Bcl-2 inhibitor in China, the US, the UK and Spain for advanced lymphoma indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!